Infinity Bio announced on June 18, 2025, the successful closing of an $8 million Series A financing round, led by Illumina Ventures. The investment will support platform innovation, commercial scaling, and new service development for antibody reactome profiling, an emerging field critical to understanding immune responses.
As part of its strategic plan, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. The proceeds will also be used to accelerate the development of Infinity Bio's proprietary MIPSA™ platform and launch new immune profiling services, including EnviroSIGHT™ in the second half of 2025.
Malek Faham, Chief Scientist at Illumina Ventures, stated that Infinity Bio's scientific prowess in providing insights into the immune system through its antibody reactome profiling platform, combined with Serimmune's assets, represents a 'game changer' for biomedical researchers. This strategic investment expands Illumina's ecosystem into a new category of immune system intelligence.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.